What is Barinthus Biotherapeutics plc (BRNS) stock price today?

Barinthus Biotherapeutics plc (BRNS) currently trades at $0.60 per share. The stock has a market capitalization of $26.23M and a P/E ratio of —x.

Is BRNS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Barinthus Biotherapeutics plc has a Smart Value Score of 32/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is 0.22.

Is Barinthus Biotherapeutics plc financially healthy?

Barinthus Biotherapeutics plc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of 0.22 places it in the distress.

BRNS

Barinthus Biotherapeutics plc

NASDAQ: BRNS · HEALTHCARE · BIOTECHNOLOGY

$0.60

-1.66% today

Updated 2026-04-29

Market cap

$26.23M

P/E ratio

—

P/S ratio

2.17x

EPS (TTM)

$-1.64

Dividend yield

—

52W range

$1 – $3

Volume

0.0M

Market cap

$26.23M

P/E ratio

—

P/S ratio

2.17x

EPS (TTM)

$-1.64

Dividend yield

—

52W range

$1 – $3

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

0.2

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$5.50

+816.82%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.14x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z 0.22 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-4.20M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$44.70M	$802000.00	$14.97M	$0.00	$0.00
Net income	$5.34M	$-73.35M	$-61.07M	$-66.43M	$-11.09M
EPS	—	—	—	—	$-1.64
Free cash flow	$-20.57M	$-56.34M	$-29.83M	$-48.02M	$-4.20M
Profit margin	11.95%	-9,145.51%	-408.00%	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
BRNS	$26.23M	32	3.7	3.0	5.0	6.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Barinthus Biotherapeutics plc trades at $0.60. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 0.22, it sits in the distress.

Frequently asked questions

What is Barinthus Biotherapeutics plc's stock price?

Barinthus Biotherapeutics plc (BRNS) trades at $0.60.

Is Barinthus Biotherapeutics plc overvalued?

Smart Value Score 32/100 (Grade F, Strong Sell).

What is the price target of Barinthus Biotherapeutics plc (BRNS)?

The analyst target price is $5.50, representing +816.8% upside from the current price of $0.60.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

0.22 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio2.17x

ROE-65.00%

Beta-0.60

50D MA$0.60

200D MA$0.94

Shares out0.04B

Float0.03B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

BRNS vs LLY →BRNS vs JNJ →BRNS vs ABBV →Stock screener →